XML 35 R20.htm IDEA: XBRL DOCUMENT v3.19.3
Fair Value Measurements (Tables)
9 Months Ended
Sep. 30, 2019
Fair Value Measurements [Abstract]  
Assets Measured at Fair Value on a Recurring Basis

The following tables present the major security types we held at September 30, 2019 and December 31, 2018 that we regularly measure and carry at fair value. At September 30, 2019 and December 31, 2018, our ProQR investment was subject to trading restrictions that extend to the fourth quarter of 2019; as a result, we included a lack of marketability discount in valuing this investment, which is a Level 3 input. The amount we owned in ProQR did not change from December 31, 2018 to September 30, 2019. The tables below segregate each security type by the level within the fair value hierarchy of the valuation techniques we utilized to determine the respective securities’ fair value (in thousands):



 
At
September 30, 2019
   
Quoted Prices in
Active Markets
(Level 1)
   
Significant Other
Observable Inputs
(Level 2)
   
Significant
Unobservable Inputs
(Level 3)
 
Cash equivalents (1)
 
$
202,904
   
$
202,904
   
$
   
$
 
Corporate debt securities (2)
   
1,296,598
     
     
1,296,598
     
 
Debt securities issued by U.S. government agencies (3)
   
283,365
     
     
283,365
     
 
Debt securities issued by the U.S. Treasury (4)
   
366,272
     
366,272
     
     
 
Debt securities issued by states of the U.S. and political subdivisions of the states (3)
   
43,265
     
     
43,265
     
 
Other municipal debt securities (3)
   
2,948
     
     
2,948
     
 
Investment in ProQR Therapeutics N.V. (5)
   
606
     
     
     
606
 
Total
 
$
2,195,958
   
$
569,176
   
$
1,626,176
   
$
606
 



 
At
December 31, 2018
   
Quoted Prices in
Active Markets
(Level 1)
   
Significant Other
Observable Inputs
(Level 2)
   
Significant
Unobservable Inputs
(Level 3)
 
Cash equivalents (1)
 
$
146,281
   
$
146,281
   
$
   
$
 
Corporate debt securities (6)
   
1,252,960
     
     
1,252,960
     
 
Debt securities issued by U.S. government agencies (3)
   
276,612
     
     
276,612
     
 
Debt securities issued by the U.S. Treasury (7)
   
260,154
     
260,154
     
     
 
Debt securities issued by states of the U.S. and political subdivisions of the states (3)
   
79,942
     
     
79,942
     
 
Investment in ProQR Therapeutics N.V. (5)
   
1,349
     
     
     
1,349
 
Total
 
$
2,017,298
   
$
406,435
   
$
1,609,514
   
$
1,349
 



The following footnotes reference lines on our condensed consolidated balance sheet:


(1)
Included in cash and cash equivalents.


(2)
$16.6 million was included in cash and cash equivalents, with the difference included in short-term investments.


(3)
Included in short-term investments.


(4)
$3.0 million was included in cash and cash equivalents, with the difference included in short-term investments.


(5)
Included in other current assets.


(6)
$50.2 million was included in cash and cash equivalents, with the difference included in short-term investments.


(7)
$14.2 million was included in cash and cash equivalents, with the difference included in short-term investments.